Newsmeme!
Discover News you didn't know existed

• home
• news
• tagging
• how it works
• about
• data

Rheumatoid Factors

News

POZEN Announces Positive Top Line Results for Its PN 400 Phase 3 Trials

Published December 3, 2008, 5:00 am, Business Wire via Yahoo! Finance

CHAPEL HILL, N.C.----POZEN Inc. , today announced positive Phase 3 trial results for its PN 400 product candidate conducted by POZEN under an agreed Special Protocol Assessment with the FDA.

Full Story

Tags

No tags found at this time. Be the first to tag this news item, learn more.

Imagery

Related Rheumatoid Factors Stories

From Various News Sources

PN 400 Phase III Studies Show Clinically Meaningful Benefit in ... - WebWire
AstraZeneca and POZEN Inc., co-development partner for the investigational compound PN 400, have announced today results from two Phase III studies, PN 400-301 and PN 400-302 comparing PN 400 (enteric-coated naproxen 500 mg and immediate release ...

POZEN Announces Positive Top Line Results for Its PN 400 Phase 3 ... - Carolina Newswire
CHAPEL HILL, N.C. --POZEN Inc. (NASDA Q: POZN), today announced positive Phase 3 trial results for its PN 400 product candidate (enteric coated naproxen 500 mg and immediate release esomeprazole 20 mg) conducted by POZEN under an agreed Special ...

Related Social Bookmarks

None found at this time.